In a new study, researchers found statins are linked with reduced death risk in people with peripheral arterial disease, even when started late after diagnosis.
In addition, patients who stop the drug are at similar risk to those who never start.
The research shows the importance of starting and adhering to lifelong medication, preferably at a high dose.
The research was conducted by a team from Bern University Hospital.
Around 200 million people worldwide have peripheral arterial disease (PAD), a condition in which arteries in the legs are clogged.
This restricts blood flow to the legs and raises the chances of stroke and heart attack.
Around 30% of patients have pain and cramping in their legs when they walk—referred to as intermittent claudication—while others have gangrene in the feet due to poor circulation.
Statins are recommended for all patients with PAD, together with smoking cessation, exercise, healthy diet, and weight loss.
Statins diminish the risk of stroke and heart attack by reducing low-density lipoprotein (LDL) cholesterol, which causes blocked arteries (atherosclerosis).
But adherence to statins is low: over the past five years, just 57% of patients in Europe took the medication as directed. In 2016 to 2017, only one-third of patients on statins reached the LDL cholesterol target of below 1.8 mmol/L (70 mg/ dl).
This study examined whether adherence to statin therapy influenced survival in patients with symptomatic PAD.
The team enrolled 691 patients admitted to hospital between 2010 and 2017 and followed-up for a median of 50 months.
At the beginning of the study, 73% of patients were on statins, increasing to 81% at the 50-month follow-up.
The dose of the drug also increased between the two time periods, which was paralleled by a significant drop in LDL cholesterol from 97 to 82 mg/dL.
The team found patients who stopped taking a statin had a similar mortality rate (33%) to those who never took the drug (34%).
Adhering to statins throughout the 50 months was linked with a 20% rate of death.
Taking high-dose statins throughout the study was linked with the lowest mortality rate (10%) while reducing the dosage during the study was related to the highest death rate (43%).
The team says the study shows that adherence to statins is essential for the best prognosis.
They suggest that it is never too late to start medication and benefit from it.
On top of that, it is crucial not to reduce the dose because LDL cholesterol levels rise again, thus increasing the overall risk on top of the residual risk for further events.
The lead author of the study is Dr. Jörn Dopheide of Bern University Hospital, Switzerland.
The study was presented today at ESC Congress 2019 together with the World Congress of Cardiology.
Copyright © 2019 Knowridge Science Report. All rights reserved.
